Urgent Trial in Congo Tests Key Therapies Against Deadly Bundibugyo Virus
In a critical global health effort, the PARTNERS clinical trial has officially begun enrolling patients in the Democratic Republic of the Congo (DRC) to test the effectiveness of two promising antiviral therapies against the deadly Bundibugyo Virus Disease (BVD). This adaptive platform trial, launched on July 2-3, 2026, aims to find the first approved treatment for BVD, a severe form of Ebola virus disease, which has no specific licensed therapies or vaccines to date. With over 1,400 cases and nearly 440 deaths reported in the DRC alone since the outbreak started, finding effective treatments is paramount.
















